Hmmm... not sure I fully agree with this. The general consensus/assumption amongst the members of this community seems to be that, in the case of Auris Medical, it is the drug itself which is at fault. What if in fact it is the not the drug that is at fault, but the inability to demonstrate efficacy due to factors such as:
If the drug is at fault, then it's easy enough: wait for the next big thing to hit the news. But... if other factors are at play, then those "next big things" to come along may well be subject to the same problems as we have seen with AM-101. And history will repeat itself, in that case.
- Obtaining a standardized patient profile which specifically matches the etiology dimensions required
- Clinical trial design
- Placebo response
- Efficacy variables available for assessment (e.g. how to rate an improvement such as via MML and/or the TFI)
Well... in the 'dark scientific age' we live in, pre-clinical trails on animals who can't tell us if they have tinnitus, nor if any intervention is effective in supressing it, are considered common practice in drug discovery. Take in account that a substantial part of medicines now in use are discovered by sheer luck... hell we even don't now exactly why a common painkiller like paracetamol acts on the biology of humans... we learn by trail and error... not by reasoning and developing drugs with science based methods...
This is, from my point of view, the core reason why Auris failed, and many others will fail in the future, till some pharma company wins the lottery by pure luck.
In addition, the consistent inability to bring a drug to market is not going to please investors. Simply put: why risk your investment when you can place your money earning the same ROI with a lower risk somewhere else? So, results such as those seen in the AM-101 trial or the QUIET-1 study could have wider implications.
Public health related matters should be considered common goods. Approaching drug discovery with capitalistic ideas leads to corruption of goals. Scientist won't work for proving the efficacy of new drug but to save the earnings of shareholders. This is why so many ineffective garbage (like many anti-depressants) or dangerous drugs (like our beloved Retigabine) is still pushed to the market.
And lastly, if Auris Medical would have had more success early on with AM-101 and AM-111, they could have become the experts in the field by cementing their market position against competitors. This could have led them to earn revenue needed for further research and eventually become the experts and develop additional therapies down-the-road. Now Auris Medical looks like a company struggling for survival and perhaps this may end up with the tinnitus community losing out on a lot of progress and collateral damage.
No, they would first of all protect their 'discovery' by patents and stop others from using their data to further improve efficacy. Second they would build upon minor improvements on the same half proven mechanism of action to extend patents and generate more revenue. It's like cars. The past 100 years every car manufacturer played for safe by improving little and shoving up the same in a new package again and again...till...
Musk... we need many more Musks... visionairs who aren't afraid of taking risks and are considering money as an instrument... not the goal of our existence...